$LLY with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $LLY after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 75%. Longby EPSMomentum1
BUY every dips for LLYEarning reports: Eli Lilly (NYSE:LLY) Q3 results beat analysts' estimates but the company lowered its FY22 outlook. Q3 non-GAAP EPS rose +12% Y/Y to $1.98, while revenue increased +2.5% Y/Y to $6.94B. The company said the revenue growth was driven by a 14% increase in volume, partially offset by a 7% decline due to lower realized prices and a 4% decrease from unfavorable impact of foreign exchange rates. Sales of diabetes therapies Trulicity rose +16% Y/Y to $1.85B, and Jardiance +47% to $573.3M. New drug Mounjaro for type 2 diabetes saw sales of $187.3M. Revenue from COVID-19 antibodies grew +78% Y/Y to $386.6M. Meanwhile, Olumiant sales fell -55% to $182.9M. Breast cancer drug Verzenio sales increased +84% Y/Y to $617.7M. Cancer therapy Retevmo revenue grew 21% to $40.5M. Gastric cancer drug Tyvyt sales fell -39% Y/Y to $76.8M. Meanwhile, Migraine drug Emgality revenue grew +20% Y/Y to $168.5M. However, sales of chemotherapy Alimta declined -74% Y/Y to $119.4M. Revenue from Forteo, which is used to treat postmenopausal women who have osteoporosis, declined -12% Y/Y to $177.1M. Lilly added that revenue in the U.S. increased 11% to $4.42B, but revenue outside the U.S. fell 9% to $2.52B. Gross margin as a percent of revenue was 77.3%, a decrease of 1.6 percentage points compared with Q3 2021. Q3 research and development expenses increased 6% Y/Y to $1.80B. Outlook: Lilly said it now expects 2022 revenue to be between $28.5B and $29.0B (prior outlook provided during Q2 results was $28.8B to $29.3B) consensus $28.76B. The company said the new revenue outlook includes an additional $300M unfavorability from foreign exchange rates since its previous guidance, for a total impact of ~$1B for the full year. Lilly now anticipates non-GAAP EPS to be between $7.70 and $7.85 (prior outlook $7.90 to $8.05) consensus $7.95. GAAP EPS is expected between $6.50 to $6.65 (prior range $6.50 to $6.65). The company said the reductions in the reported and non-GAAP EPS ranges reflect the unfavorable impact of foreign exchange rates and $0.06 EPS impact linked with acquired IPR&D and development milestone charges in Q3 2022. Fundamental: Eli Lilly and Company (NYSE:LLY) is one of the leaders in the treatment of diabetes and obesity and is committed to expanding its presence in the treatment of cancer and autoimmune diseases. In the past, the company showed significant growth in revenue, EBITDA, and margins, which attracted institutional investors and contributed to the increase in the company's capitalization. Mr. Market is capitalizing on FDA approval and Medicare's positive decision on donanemab, which is being investigated in phase 3 clinical trial. However, the controversial efficacy results and the negative safety profile shown in phase 2 call into question the objectivity of assessing the prospects of this medicine. Financial indicators that are significantly higher than the average values of the pharmaceutical industry, declining revenue, a relatively small number of product candidates in Phase 2/3 clinical trials, will be one of the reasons for the start of a corrective movement in the company's shares. And you can also find a lot of articles on market says they are waiting for "The Correction". Possibly I will say no, buy every dip! Technical: The trendline support and resistance is from weekly basis, and since 8&21 MAs already catching up on daily basis, therefore, there's no reason that we say it is the top of the LLY, because I could not see the uptrend is end right here. Keep making new highs are always scary, however, if LLY can keep deliver the good financial result, why it can not making another new high? Can we see any down pressures? Therefore, from trend trading side of view, buy every dips if trend still there. The investments and idea published may not be suitable for all investors. If you have any doubts as to the merits of an investment, you should seek advice from independent financial advisor or other professionals to determine what may be best for your individual needs. We do not and cannot guarantee that your use of our APP and/or any of its features will generate profits. All opinions, news, reviews, research, analysis, prices, or other information contained on or provided via this site are provided on an “as is” basis as general market commentary and/or expressions of opinion only. Information may not be complete, accurate or up to date and may not be suitable for every individual, nor be a suitable basis for an investment decision. No representation, warranty, undertaking, assurance or guarantee (express or implied) is made or given as to the availability, adequacy, accuracy, completeness, reasonableness or appropriateness of any of the information or opinions provided or expressed on or through this site. There is no obligation to notify you of any corrections or modifications.Longby SoundsgoodTFtalks112
Eli lilly Pre earnings If parabolic was a stock. This is exactly how Adobe and Google looked in late 2021 before they lost half of their value. White lines - Primary trend Yellow lines - Super uptrend. 2023 will be rough for this one, as all stock return to their primary trendline.. But for now I'll settle for a pullback to yellow support line around 320 Shortby ContraryTrader666
LLYthe health services and health technology sectors were the first to receive investment and bullish speculative pressures as the dollar fell that is, drugs and vaccines never go into crisis .. even LLY has never even dropped below the 200 daily moving average this year, like very few stocks and has now confirmed a bullish symmetrical triangle, I buy now and on GAP 343 retracementLongby dan686081
LLY One-Day Reversal?double speculation? on 21 September false BO on Descending Triangle (final phase of the Rounding Top) and yesterday One-Day ReversalShortby dan686080
LLY daily indecision candle overpriced at all time highOrder SELL LLY NYSE Stop 325.50 LMT 325.50 will be automatically canceled at 20230101 00:00:00 EST LLY daily indecision candle overpriced at all time high retest gap with exhaustion volume.Shortby MishaSuvorov110
Descending TriangleThis one broke to the upside and also broke the resistance of the rectangle. There must have been a good news event but I am not sure. I guess we just never know! No recommendation. This breakout is almost exactly the height of the wide end of the triangle so far. It could go higher but measuring the wide end and projecting it from the point of the breakout is a one way to guesstimate a targetby lauralea0
RectangleDescending triangle that is neutral until a trendline is broken. The Rectangle is also a neutral pattern. Upgraded by analysts. Also a possible H&S pattern. No recommendationby lauraleaUpdated 1
$LLY Setting up Nicely for a Call$LLY Bouncing off 302 (.681) Fibonacci. Trendsi indicators are almost connecting for a call opportunity. Green EMA (Middle line), Money Momentum flowing right on top of the EMA. As well the RSI right at 40. Waiting for the Buy Signal to confirm movement to the upside. Even with Powell speech, LLY was not really affected by it. Still trading within its zone when the Fibonacci was place back in 16 June 2022. Longby rc92573
LLY , LONGTook a B1 in LLY near close Above its GLB in lower third of uptrend channel 50 sma takeback today ( my cue) Morning starish reversal pattern aug 10-13 followed by WP through 10/21 ema's Entry 317.16 Stop - 309.38 PT1 - 324.93 , sell 1/4 , stop up to half PT1 - 332.71 , then add mode ~Longby NAK1987Updated 222
Eli Lilly and CompanyEli Lilly and Company Price 301.17 P/E (Trailing) 48.61 Change -3.44 P/E (Forward) 32.37 Change % -1.13% Dividend Yield 1.29% Prev Close 304.61 Dividend 3.92 Volume 2,198,663 Market Cap 293.72B Year Low 220.20 EPS (Trailing) 6.27 Year High 335.33 EPS (Forward) 9.41Shortby zrrsysUpdated 110
$LLY with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $LLY after a Negative Under reaction following its earnings release placing the stock in drift D with an expected accuracy of 50%. Longby EPSMomentum111
LLY Shortcounter trend, RSI divergence Earning: 8/4/2022 Est. 1.72 Short 330 Stop 337 Target 310 280 Risk management is much more important than a good entry point. I am not a PRO trader. In my trading plan, the Max Risk of each short term trade should be less than 1% of an account.Shortby PlanTradePlanMMUpdated 111
Rectangle//Short if Bottom Trendline is BrokenShort if bottom trendline is broken at 282. Possibly a Rectangle Top and is a neutral pattern until a trendline is broken. I have been watching this for a while now. Earnings miss. Short if bottom trendline is broken at 282. No recommendationby lauralea2
$LLY Keep on your portfolio!Eli Lilly and Company is showing a strong momentum ahead of earning report. its one of by favorite ones. --TradeWise--Longby zakalj2
$LLY looks ready to breakout$LLY daily chart. IT closed nicely on Friday even though most of the stocks were down a lot. After an up move, it is now moving sideways inside this rectangular range. Looks ready for next upmove once we break this range on the upside. Once we break above 335, looking for a 8% up move in this one.by TraderHarneet440
7/17/22 LLYEli Lilly and Company ( NYSE:LLY ) Sector: Health Technology (Pharmaceuticals: Major) Market Capitalization: $315.073B Current Price: $331.60 Breakout price: $334.70 Buy Zone (Top/Bottom Range): $314.00-$292.90 Price Target: $364.20-$367.50 (2nd) Estimated Duration to Target: 112-120d (2nd) Contract of Interest: $LLY 10/21/22 350c Trade price as of publish date: $13.50/contractLongby lord_catnip0
Keeps on Going!LLY has had an amazing run to the upside. Some would think it is a bit overvalued here, but that does not always matter. Value is not always the most important thing it seems, so it just depends on when folks are ready to sell. It is like a "Domino" effect Be safe up there No recommendation. Spinning top right now on daily/indecisionby lauralea550
WallStreet Trading: Buysignal LLYThe stock LLY on our US watchlist just broke out of a sound base and triggered a buy signal. We are adding a 1/2 position to our US model portfolio. SL can be set at 314.9 (4% risk). Profit target is > 10%.Longby JS_TechTrading1
$LLY Breakout #fintwit #supertrend#LLY Breakout 🚀 in 1h Chart - Target 366$ 🧲 All Entry Criteria have been met: 1. Price above 10, 20 & 50 EMA ✅ 2. Consolidation Phase in Uptrend ✅ 3. Breakout on above average Volume ✅ Longby Diplo_Trades2
$LLY All Time High BreakoutBiotech/Healthcare are certainly seeing inflows of money from institutions. The RS on this name along with the clear volume accumulation is really nice. Potential consolidation into ATH Breakout. Longby irishborninvestor1
LLY Fib Circle Scenario (MACD top)Comparing two points of price and MACD The MACD is very similar in both points, very over extended This correlates well with the 1.618 fib level, which allows price to move down along the circle as the MACD retraces, as seen in the first scenario (0.618) by Bixley0
LLY New All Time HighsLLY made a New All Time High on Friday Clean Base Breakout 8 Week Long Base Price above 200DMA Volume is higher than 50 Day Average Volume Measured Target: 353Longby zhasan92hz2